• For Researchers

Richard Martin: How to write an award-winning population research funding proposal

Richard Martin, leader of the CRUK-funded CAP trial of prostate cancer screening, spoke to us about the study’s impact and his advice for funding applicants. Richard Martin, leader of the CRUK-funded CAP trial of prostate cancer screening, spoke to us about the study’s impact and his advice for funding applicants.

19 December 2019

• Science & Technology
• Health & Medicine

Our biggest cancer news stories of 2019

We look back at the top cancer news stories of 2019, including the first trial of a cancer breath test. We look back at the top cancer news stories of 2019, including the first trial of a cancer breath test.

17 December 2019

• Science & Technology

First-in-human trial for new lung cancer immunotherapy

Cancer Research UK and VOLT, announce a new partnership to bring a novel immunotherapeutic vaccine strategy to patients with lung cancer Cancer Research UK and VOLT, announce a new partnership to bring a novel immunotherapeutic vaccine strategy to patients with lung cancer

17 December 2019

• Science & Technology
• Health & Medicine

News digest – NHS drug decisions, leukaemia treatment trials and long term anastrozole benefits

In the news this week: breast cancer drug combo made more widely available on the NHS and the long term benefits of anastrozole are revealed. In the news this week: breast cancer drug combo made more widely available on the NHS and the long term benefits of anastrozole are revealed.

14 December 2019

• For Supporters

In conversation with our Chair, Sir Borys - Finding answers to the whys

In the first of a two-part interview, we chart the remarkable journey to knighthood of Chair of Cancer Research UK, Professor Sir Leszek Borysiewicz. In the first of a two-part interview, we chart the remarkable journey to knighthood of Chair of Cancer Research UK, Professor Sir Leszek Borysiewicz.

13 December 2019

• Health & Medicine

Blood test can quickly match advanced breast cancer patients to targeted treatments

New trial results show that a blood test can identify rare types of advanced breast cancer and help patients to access the right treatment more quickly. New trial results show that a blood test can identify rare types of advanced breast cancer and help patients to access the right treatment more quickly.

12 December 2019

• Health & Medicine

Targeted ovarian cancer drug made available to more people on NHS in England

NICE has made olaparib (Lynparza), a targeted cancer drug, more widely available for people with ovarian cancer on the NHS in England. NICE has made olaparib (Lynparza), a targeted cancer drug, more widely available for people with ovarian cancer on the NHS in England.

11 December 2019

• For Supporters

The rise and rise of our ScottishPower partnership

How a £5m fundraising target grew to over £25m raised towards beating cancer, united employees and engaged more than 500,000 customers How a £5m fundraising target grew to over £25m raised towards beating cancer, united employees and engaged more than 500,000 customers

9 December 2019

• Health & Medicine

Targeted ovarian cancer drug made more widely available on the NHS in Scotland

A targeted cancer drug has been approved for use on the NHS in Scotland for patients with newly diagnosed ovarian cancer that’s responded to chemotherapy. A targeted cancer drug has been approved for use on the NHS in Scotland for patients with newly diagnosed ovarian cancer that’s responded to chemotherapy.

9 December 2019

• Science & Technology
• Health & Medicine

News digest – NHS avoidable delays, sugary festive drinks, hair dye and mistletoe

In the news this week: our stats show 1 in 4 people are experience avoidable delays for their cancer diagnosis and festive hot drinks are loaded with sugar. In the news this week: our stats show 1 in 4 people are experience avoidable delays for their cancer diagnosis and festive hot drinks are loaded with sugar.

7 December 2019

• Science & Technology

So-called 'junk DNA' affects inherited cancer risk

Research reveals how genetic variations in the regions of DNA that don't code for proteins, once dismissed as 'junk DNA', can affect a person's risk of cancer. Research reveals how genetic variations in the regions of DNA that don't code for proteins, once dismissed as 'junk DNA', can affect a person's risk of cancer.

6 December 2019